by | Oct 22, 2019 | Curiel, David
— Disease indication – Cancer
Drug format – Adenoviral vector for immunotherapy/dendritic cell therapy
Drug class – Improvement
Research stage and Preliminary data:
Target – Carbohydrate biomarkers of cancer
Background:
Dendritic cells (DCs) are potent antigen presenting cell…
by | Oct 22, 2019 | Colonna, Marco, Ulland, Tyler
— Background: Alzheimer’s disease (AD) is the 6th leading cause of death in the United States, and yet causation of the disease is poorly understood and targets for therapeutic intervention are still being identified. Recently, mutations in the immune receptor TREM2 have been found to be strongl…
by | Oct 22, 2019 | Kharasch, Evan, Morrissey, Jeremiah, Singamaneni, Srikanth, Tadepalli, Sirimuvva
— Technology Description
An interdisciplinary team of researchers at Washington University have developed a sensitive, shelf-stable, label-free system for quickly quantifying biomarkers in point-of-care settings (e.g., office, ambulance or battlefield). Localized surface plasmon resonance (LSPR) off…
by | Oct 22, 2019 | Apte, Rajendra
— Technology Description
Researchers in Prof. Rajendra Apte’s laboratory developed novel methods for treating macular degeneration and other eye diseases by targeting a cholesterol transport pathway involved in the formation of new blood vessels. Age-related macular degeneration (AMD) is a lea…
by | Oct 22, 2019 | Gutmann, David, Weber, Jason
— Technology Description
Scientists at the Washington University Neurofibromatosis Center have developed a patented, first-in-class method for treating neurofibromatosis type 1 (NF1) with small molecule inhibitors of targets in the mTOR (mammalian target of rapamycin) signaling pathway. NF1 is a rel…